newsfilter
← Latest News
PR Newswire·

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (NASDAQ:AZN) to in-license the late stage monoclonal antibod